Outcome of the Board Meeting held on Monday, 10 November 2025 and Submission of the Unaudited Financial Results and Limited Review Report on Financial Result for the half year ended on ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shelter Pharma's board approved standalone unaudited financial results for the half year ended 30 September 2025, along with an unmodified limited review report from Mendajiwala & Co. Revenue from operations rose to ₹3,329.29 lakhs from ₹2,405.67 lakhs in H1 FY25, a year-on-year jump of about 38%. Profit after tax climbed to ₹450.07 lakhs (vs ₹353.64 lakhs), up roughly 27% YoY, with basic EPS at ₹3.89 (vs ₹3.06). Total assets and liabilities expanded to ₹6,689.54 lakhs (vs ₹4,833.55 lakhs at March 2025), driven mainly by a sharp rise in long-term borrowings to ₹1,350.84 lakhs (from ₹93.16 lakhs). The auditor also certified that ₹930.35 lakhs raised via convertible warrants was fully used for working capital with no deviation. No investor complaints were reported during the period.
Strong top-line and bottom-line growth is positive for shareholders, but the sizeable negative operating cash flow of ₹869 lakhs and a sharp jump in long-term borrowings flag working-capital strain that investors should monitor closely.